z-logo
open-access-imgOpen Access
Loss of PTEN-assisted G2/M checkpoint impedes homologous recombination repair and enhances radio-curability and PARP inhibitor treatment response in prostate cancer
Author(s) -
Waël Mansour,
Pierre Tennstedt,
Jennifer Volquardsen,
Christoph Oing,
Martina Kluth,
Claudia HubeMagg,
Kerstin Borgmann,
Ronald Simon,
Cordula Petersen,
Ekkehard Dikomey,
Kai Rothkamm
Publication year - 2018
Publication title -
scientific reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.24
H-Index - 213
ISSN - 2045-2322
DOI - 10.1038/s41598-018-22289-7
Subject(s) - pten , olaparib , cancer research , parp inhibitor , rad51 , dna repair , prostate cancer , synthetic lethality , homologous recombination , cancer , pi3k/akt/mtor pathway , biology , medicine , poly adp ribose polymerase , microbiology and biotechnology , signal transduction , dna , genetics , polymerase
Here we report that PTEN contributes to DNA double-strand break (DSB) repair via homologous recombination (HR), as evidenced by (i) inhibition of HR in a reporter plasmid assay, (ii) enhanced sensitivity to mitomycin-C or olaparib and (iii) reduced RAD51 loading at IR-induced DSBs upon PTEN knockdown. No association was observed between PTEN-status and RAD51 expression either in-vitro or in-vivo in a tissue microarray of 1500 PTEN-deficient prostate cancer (PC) samples. PTEN depletion and sustained activation of AKT sequestered CHK1 in the cytoplasm, thus impairing the G2/M-checkpoint after irradiation. Consistently, AKT inhibition recovered the G2/M-checkpoint and restored HR efficiency in PTEN-depleted cells. We show that, although PTEN loss correlates with a worse prognosis, it may predict for improved response of PC patients to radiotherapy. Further, we provide evidence for the use of PTEN as a biomarker for predicting the response to PARP inhibitors as radiosensitizing agents in prostate cancer. Collectively, these data implicate PTEN in maintaining genomic stability by delaying G2/M-phase progression of damaged cells, thus allowing time for DSB repair by HR. Furthermore, we identify PTEN-status in PC as a putative predictor of (i) radiotherapy response and (ii) response to treatment with PARP inhibitor alone or combined with radiotherapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here